Calmactin
Generic name: cilansetron
Treatment for: Irritable Bowel Syndrome
Cilansetron; Solvay Pharmaceuticals Suspends Registration Activites in the U.S., While Discussions in Europe Continue
On average, IBS affects more than 11% of the EU population, with total annual direct costs estimates of some £45 million in the UK alone. The common symptoms of D-IBS are diarrhea, abdominal pain/discomfort, and fecal urgency. IBS has a significant, negative impact on the quality of life for the many men and women who suffer from this condition, causing lost days of work and interfering as well with home-based, social and leisure activities.
Source: Solvay Pharmaceuticals
Posted: November 2005
Related articles
- FDA Requests Further Data on Cilansetron, Solvay's Proposed Treatment for Irritable Bowel Syndrome with Diarrhea Predominance (IBS-D) - April 1, 2005
- Solvay Pharmaceuticals, Inc. Announces 90-Day Extension of FDA Review of the New Drug Application for Cilansetron for the Treatment of Irritable Bowel Syndrome with Diarrhea Predominance (IBS-D) - December 20, 2004
- Cilansetron NDA Filing Accepted for Priority Review by the FDA for the Treatment of Irritable Bowel Syndrome with Diarrhea Predominance - September 1, 2004
- Solvay Pharmaceuticals, Inc. Submits New Drug Application to the United States Food and Drug Administration for Cilansetron toTreat Irritable Bowel Syndrome with Diarrhea Predominance in Men and Women - July 1, 2004
Calmactin (cilansetron) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.